1-(piperidin-4-yl)-1H-benzo[d]imidazole,trifluoroacetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(piperidin-4-yl)-1H-benzo[d]imidazole,trifluoroacetate
• 英文别名: 4-(1H-benzimidazol-1-yl)piperidine trifluoroacetate；1-piperidin-4-ylbenzimidazole;2,2,2-trifluoroacetic acid
• 化学式: C₂HF₃O₂*C₁₂H₁₅N₃
• 分子量: 315.295
• InChiKey: SWFPQXIQKOVATC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.59
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-(4-氯苯胺甲基)噻吩-2-磺酰氯 、 1-(piperidin-4-yl)-1H-benzo[d]imidazole,trifluoroacetate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N-[(5-{[4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of Novel, Potent, and Selective (Benzoylaminomethyl)thiophene Sulfonamide Inhibitors of c-Jun-N-Terminal Kinase

  摘要：

  Several lines of evidence support the hypothesis that c-Jun N-terminal kinases (JNKs) play a critical role in a wide range of disease states including cell death (apoptosis)-related and inflammatory disorders (epilepsy, brain, heart and renal ischemia, neurodegenerative diseases, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel syndrome). The screening of a compound collection led to the identification of a 2-(benzoylaminomethyl)thiophene sulfonamide (AS004509, compound I) as a potent and selective JNK inhibitor. Chemistry and structure-activity relationship (SAR) studies performed around this novel kinase-inhibiting motif indicated that the left and central parts of the molecule were instrumental to maintaining potency at the enzyme. Accordingly, we investigated the JNK-inhibiting properties of a number of variants of the right-hand moiety of the molecule, which led to the identification of 2-(benzoylaminomethyl)thiophene sulfonamide benzotriazole (AS600292, compound 50a), the first potent and selective JNK inhibitor of this class which demonstrates a protective action against neuronal cell death induced by growth factor and serum deprivation.

  DOI：

  10.1021/jm031112e
• 作为产物：
  描述：

  tert-butyl 4-(1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 、 异丙醚 为溶剂， 以100%的产率得到1-(piperidin-4-yl)-1H-benzo[d]imidazole,trifluoroacetate
  参考文献：
  名称：

  Diphenylalkylamine derivatives useful as opioid receptor agonists

  摘要：

  一种具有与阿片受体δ亲和力的物质，其由以下一般公式（I）表示：其中，X代表一般公式的一个基团：—CO—N（R5）（R6）（II）等，n代表1至3，R1和R2代表氢原子、卤素原子、低碳烷基团等，R3代表氢原子、卤素原子、低碳烷基团等，R4代表饱和或不饱和的单环或双环碳环基团等，R5到R12代表氢原子、低碳烷基团等，R3和R4、R5和R6、R7或R8和R9以及R10可能相互结合形成环状结构，并且包括该物质作为活性成分的用于预防和/或治疗中枢神经系统疾病和外周神经系统疾病的药物。

  公开号：

  US20030176693A1

文献信息

• Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor
  作者：Simone Gastaldi、Valentina Boscaro、Eleonora Gianquinto、Christina F. Sandall、Marta Giorgis、Elisabetta Marini、Federica Blua、Margherita Gallicchio、Francesca Spyrakis、Justin A. MacDonald、Massimo Bertinaria

  DOI：10.3390/molecules26133975

  日期：——

  In the search for new chemical scaffolds able to afford NLRP3 inflammasome inhibitors, we used a pharmacophore-hybridization strategy by combining the structure of the acrylic acid derivative INF39 with the 1-(piperidin-4-yl)1,3-dihydro-2H-benzo[d]imidazole-2-one substructure present in HS203873, a recently identified NLRP3 binder. A series of differently modulated benzo[d]imidazole-2-one derivatives

  在寻找能够提供 NLRP3 炎症小体抑制剂的新化学支架时，我们使用了药效团杂交策略，将丙烯酸衍生物 INF39 的结构与 1-(piperidin-4-yl)1,3-dihydro-2 H -benzo[d]imidazole-2-one 亚结构存在于 HS203873 中，这是一种最近发现的 NLRP3 粘合剂。设计并合成了一系列不同调制的苯并 [d] 咪唑-2-one 衍生物。获得的化合物在体外进行筛选，以测试它们抑制 LPS/ATP 刺激的 PMA 分化的 THP-1 细胞中 NLRP3 依赖性细胞焦亡和 IL-1β 释放的能力。使用新开发的测定法评估所选化合物降低人重组 NLRP3 ATPase 活性的能力。从该筛选中，化合物9、13和18能够浓度依赖性地抑制 LPS/ATP 刺激的人类巨噬细胞中 IL-1β 的释放，成为该系列中最有前途的 NLRP3 抑制剂。计算模拟用于构建 NLRP3
• Diphenylalkylamine derivatives useful as opioid receptor agonists
  申请人：——

  公开号：US20030176693A1

  公开（公告）日：2003-09-18

  A substance having affinity for an opioid &dgr; receptor, which is represented by the following general formula (I): 1 wherein, X represents a group of the general formula: —CO—N(R 5 )(R 6 ) (II) and the like, n represents 1 to 3, R 1 and R 2 represent a hydrogen atom, a halogen atom, a lower alkyl group and the like, R 3 represents a hydrogen atom, a halogen atom, a lower alkyl group and the like, R 4 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, R 5 to R 12 represent a hydrogen atom, a lower alkyl group and the like, and R 3 and R 4 , R 5 and R 6 , R 7 or R 8 and R 9 and R 10 may bind to each other to form a cyclic structure, and a medicament useful for preventive and/or therapeutic treatment of central nervous system diseases and peripheral nervous system diseases comprising the substance as an active ingredient.

  一种具有与阿片受体δ亲和力的物质，其由以下一般公式（I）表示：其中，X代表一般公式的一个基团：—CO—N（R5）（R6）（II）等，n代表1至3，R1和R2代表氢原子、卤素原子、低碳烷基团等，R3代表氢原子、卤素原子、低碳烷基团等，R4代表饱和或不饱和的单环或双环碳环基团等，R5到R12代表氢原子、低碳烷基团等，R3和R4、R5和R6、R7或R8和R9以及R10可能相互结合形成环状结构，并且包括该物质作为活性成分的用于预防和/或治疗中枢神经系统疾病和外周神经系统疾病的药物。
• Phenoxyalkylamine derivatives useful as opioid delta receptor ligands
  申请人：Tsushima Masaki

  公开号：US20050148583A1

  公开（公告）日：2005-07-07

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于神经系统疾病的预防和/或治疗的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐作为活性成分： 其中，X代表以下通式（II），（III），（IV），（V）或（VI）所表示的基团，“A”代表饱和或不饱和的3-至6-成员的碳环基团等，“B”代表CH2等，“n”代表0至2，“R1”代表氢原子，卤原子等，“R2”，“R3”和“R7”至“R14”代表氢原子，可被取代的较低烷基基团等，“R4”代表氢原子，可被取代的较低烷基基团等，“R5”代表氢原子，卤原子等，“R6”代表饱和或不饱和的单环或双环碳环基团等，“R5”和“R6”，“R7”和“R8”，“R9”和“R10”，或“R11”和“R12”可以结合在一起形成环状结构。
• DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1277737A1

  公开（公告）日：2003-01-22

  A substance having affinity for an opioid δ receptor, which is represented by the following general formula (I): wherein, X represents a group of the general formula: -CO-N(R5)(R6) (II) and the like, n represents 1 to 3, R1 and R2 represent a hydrogen atom, a halogen atom, a lower alkyl group and the like, R3 represents a hydrogen atom, a halogen atom, a lower alkyl group and the like, R4 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, R5 to R12 represent a hydrogen atom, a lower alkyl group and the like, and R3 and R4, R5 and R6, R7 or R8 and R9 and R10 may bind to each other to form a cyclic structure, and a medicament useful for preventive and/or therapeutic treatment of central nervous system diseases and peripheral nervous system diseases comprising the substance as an active ingredient.

  一种对阿片δ受体具有亲和力的物质，由以下通式(I)表示： 其中，X 代表通式中的基团：-R1 和 R2 代表氢原子、卤素原子、低级烷基等，R3 代表氢原子、卤素原子、低级烷基等，R4 代表饱和或不饱和的单环或双环碳环基团等，R5 至 R12 代表氢原子、低级烷基等、R3和R4、R5和R6、R7或R8以及R9和R10可以相互结合形成环状结构，以及一种用于预防和/或治疗中枢神经系统疾病和周围神经系统疾病的药物，该药物包含该物质作为活性成分。
• PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1256575B1

  公开（公告）日：2005-08-17